Effect of intraperitoneal pristane on established immunity to the adj-PC-5 plasmacytoma.
D000473:Alkanes / Q000494:pharmacology*; D000814:Aniline Compounds / Q000627:therapeutic use; D000818:Animals; D002460:Cell Line; D005260:Female; D006084:Graft Rejection; D007274:Injections, Intraperitoneal; D007279:Injections, Subcutaneous; D051379:Mice; D008807:Mice, Inbred BALB C; D009150:Mustard Compounds / Q000627:therapeutic use; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000276:immunology; D010954:Plasmacytoma / Q000188:drug therapy / Q000276:immunology*; D012878:Skin Neoplasms / Q000188:drug therapy / Q000276:immunology*; D014184:Transplantation, Homologous
D000473:Alkanes; D000814:Aniline Compounds; D009150:Mustard Compounds